Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI

Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI

Background: Omalizumab provides clinical benefits to a fraction of patients with asthma. It remains unclear why some patients do not respond to omalizumab therapy. Objective: We sought to investigate whether omalizumab could alter serum cytokine and chemokine levels that could be associated with ast...

Full description

Saved in:
Bibliographic Details
Main Authors: Agnes Yang, BS, Chao Gu, PhD, Katherine Upchurch, PhD, Adrien Caffiers, MS, Mark Millard, MD, Laurie Baert, PhD, HyeMee Joo, PhD, SangKon Oh, PhD
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
Asthma
IgE
anti-IgE
omalizumab
serum
cytokine
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829325000633
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2772829325000633

Similar Items